Literature DB >> 17534622

Chitotriosidase as a marker of disease activity in sarcoidosis.

Jürgen Brunner1, Sabine Scholl-Bürgi, Lothar-Bernd Zimmerhackl.   

Abstract

Sarcoidosis is a chronic granulomatous inflammation. The clinical spectrum in childhood is heterogeneous. Angiotensin converting enzyme (ACE) activity is used as a marker for disease activity. Human chitotriosidase is produced in macrophages. In this study serum chitotriosidase levels were significantly higher in active sarcoidosis, than in inactive disease or healthy controls. Serum chitotriosidase concentrations may be a useful marker for monitoring disease activity in sarcoidosis.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17534622     DOI： 10.1007/s00296-007-0363-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  10 in total

1.  Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.

Authors:  B Czartoryska; A Tylki-Szymańska; A Lugowska
Journal:  Clin Biochem       Date:  2000-03       Impact factor: 3.281

2.  Muscle involvement in childhood sarcoidosis and need for muscle biopsy.

Authors:  A V Ramanan; A D Thimmarayappa; E M Baildam
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

3.  The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update.

Authors:  H Michelakakis; E Dimitriou; I Labadaridis
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  Juvenile sarcoidosis presenting as Crohn's disease.

Authors:  Jürgen Brunner; Consolato Sergi; Thomas Müller; Ingmar Gassner; Friederike Prüfer; Lothar Bernd Zimmerhackl
Journal:  Eur J Pediatr       Date:  2006-03-18       Impact factor: 3.183

Review 5.  Sarcoidosis: a pediatric perspective.

Authors:  A K Shetty; A Gedalia
Journal:  Clin Pediatr (Phila)       Date:  1998-12       Impact factor: 1.168

6.  Marked increase of methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase activity in plasma from Gaucher disease patients.

Authors:  W R den Tandt; F van Hoof
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 7.  A review of angiotensin converting enzyme in health and disease.

Authors:  R K Allen
Journal:  Sarcoidosis       Date:  1991-09

8.  Elevated plasma chitotriosidase activity in various lysosomal storage disorders.

Authors:  Y Guo; W He; A M Boer; R A Wevers; A M de Bruijn; J E Groener; C E Hollak; J M Aerts; H Galjaard; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

9.  Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT).

Authors:  B Czartoryska; A Tylki-Szymańska; D Górska
Journal:  Clin Biochem       Date:  1998-07       Impact factor: 3.281

10.  Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins.

Authors:  G H Renkema; R G Boot; A O Muijsers; W E Donker-Koopman; J M Aerts
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157
  10 in total
  3 in total

1.  Human chitotriosidase: a sensitive biomarker of sarcoidosis.

Authors:  Elena Bargagli; David Bennett; Claudia Maggiorelli; Pasquale Di Sipio; Maria Margollicci; Nicola Bianchi; Paola Rottoli
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

Review 2.  Gaucher disease: new developments in treatment and etiology.

Authors:  Ozgur Harmanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

3.  Verifying Sarcoidosis Activity: Chitotriosidase versus ACE in Sarcoidosis - a Case-control Study.

Authors:  Spasoje Popević; Zorica Šumarac; Dragana Jovanović; Dragan Babić; Mihailo Stjepanović; Snežana Jovičić; Dragana Šobić-Šaranović; Snežana Filipović; Branko Gvozdenović; Maja Omčikus; Anđela Milovanović; Jelica Videnović-Ivanov; Ana Radović; Vladimir Žugić; Violeta Mihailović-Vučinić
Journal:  J Med Biochem       Date:  2016-11-02       Impact factor: 3.402
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.